Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
This is a Heparin with low molecular weight
There is published evidence of a lack of anti-coagulant activity in the serum of breastfed infants whose mothers were treated with Enoxaparin.
The high molecular weight of the so-called standard or non-fragmented Heparin and others called low weight Heparins makes that excretion into breast milk very unlikely.
There is scientific proof on the lack of excretion of Dalteparin into breast milk.
In addition, Heparin derived drugs are inactivated in the gut and they are not absorbed at all, hence, oral bioavailability is nil.
The risk of Heparin-induced Thrombocytopenia and Osteoporosis is lower with low weight Heparin among treated adults.